Lilly Q4 revenue of $19.29 billion, up 43% year-over-year; expected full-year revenue of $80 billion to $83 billion | Earnings Report Insights

SnapshotLaborer · 2026-02-04T11:59:49+00:00

Eli Lilly's adjusted earnings per share for the fourth quarter were $7.54, up 41% year-over-year, with revenue reaching $19.29 billion, a 43% increase year-over-year, surpassing market expectations. The full-year revenue is expected to be between $80 billion and $83 billion, also above market expectations.

SnapshotLaborer

2026-02-04 11:59:49

Abstract generation in progress

Eli Lilly’s adjusted earnings per share for Q4 were $7.54, compared to $5.32 in the same period last year. Q4 revenue was $19.29 billion, up 43% year-over-year, beating market expectations of $18.01 billion. Full-year revenue is projected to be between $80 billion and $83 billion, with market expectations of $77.71 billion.

More updates coming soon…

Risk Warning and Disclaimer

The market carries risks; investments should be made cautiously. This article does not constitute personal investment advice and does not consider individual users’ specific investment goals, financial situations, or needs. Users should consider whether any opinions, views, or conclusions in this article are suitable for their particular circumstances. Invest at your own risk.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.